1-20 of 22
Jeffrey G. Supko
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I study of adavosertib with radiation therapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma

Eudocia Q. Lee, Brian M. Alexander, Carlos G. Romo, Jeffrey G. Supko, Nathalie Y.R. Agar, Zahra Talebi, Manmeet S. Ahluwalia, Arati S. Desai, Jorg Dietrich, Thomas J. Kaley, David M. Peereboom, Jennifer Gantchev, Gerard Baquer, Sandro Santagata, Naoko Takebe, Serena Desideri, Joy D. Fisher, Megan Sims, Xiaobu Ye, Keith L. Ligon, Louis B. Nabors, Stuart A. Grossman, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-24-2311
Published: 17 January 2025
View article titled, Phase I study of adavosertib with radiation therapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma
Open the PDF for Phase I study of adavosertib with radiation therapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma in another window
Includes: Supplementary data
Journal Articles

Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib

Abhishek Tripathi, Jeffrey G. Supko, Kathryn P. Gray, Zachary J. Melnick, Meredith M. Regan, Mary-Ellen Taplin, Atish D. Choudhury, Mark M. Pomerantz, Joaquim Bellmunt, Channing Yu, Zijie Sun, Sandy Srinivas, Philip W. Kantoff, Christopher J. Sweeney, Lauren C. Harshman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6122–6131.
https://doi.org/10.1158/1078-0432.CCR-20-2306
Published: 01 December 2020
View article titled, Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib
Open the PDF for Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors

Vandana G. Abramson, Jeffrey G. Supko, Tarah Ballinger, James M. Cleary, John F. Hilton, Sara M. Tolaney, Nicole G. Chau, Daniel C. Cho, Joseph Pearlberg, Joanne Lager, Geoffrey I. Shapiro, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3520–3528.
https://doi.org/10.1158/1078-0432.CCR-16-1764
Published: 13 July 2017
View article titled, Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors
Open the PDF for Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors in another window
Journal Articles

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dan T. Vogl, Noopur Raje, Sundar Jagannath, Paul Richardson, Parameswaran Hari, Robert Orlowski, Jeffrey G. Supko, David Tamang, Min Yang, Simon S. Jones, Catherine Wheeler, Robert J. Markelewicz, Sagar Lonial
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (13): 3307–3315.
https://doi.org/10.1158/1078-0432.CCR-16-2526
Published: 02 July 2017
View article titled, Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Open the PDF for Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma in another window
Journal Articles

Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial

Ran Xu, Fumiko Shimizu, Koos Hovinga, Kathryn Beal, Sasan Karimi, Leif Droms, Kyung K. Peck, Philip Gutin, J. Bryan Iorgulescu, Thomas Kaley, Lisa DeAngelis, Elena Pentsova, Craig Nolan, Christian Grommes, Timothy Chan, Dylan Bobrow, Adilia Hormigo, Justin R. Cross, Nian Wu, Naoko Takebe, Katherine Panageas, Percy Ivy, Jeffrey G. Supko, Viviane Tabar, Antonio Omuro
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4786–4796.
https://doi.org/10.1158/1078-0432.CCR-16-0048
Published: 02 October 2016
View article titled, Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial
Open the PDF for Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Beata Holkova, Jeffrey G. Supko, Matthew M. Ames, Joel M. Reid, Geoffrey I. Shapiro, Edward Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Connie Honeycutt, Renee M. McGovern, Maciej Kmieciak, Ellen Shrader, Martha D. Wellons, Heidi Sankala, Austin Doyle, John Wright, John D. Roberts, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1873–1883.
https://doi.org/10.1158/1078-0432.CCR-12-2926
Published: 02 April 2013
View article titled, A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Open the PDF for A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 in another window
Includes: Supplementary data
Journal Articles

Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, Dushyant V. Sahani, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Thomas A. Abrams, Nadine Jackson McCleary, Pankaj Bhargava, Alona Muzikansky, Susan Sheehan, Eileen Regan, Eamala Vasudev, Michelle Knowles, Charles S. Fuchs, David P. Ryan, Rakesh K. Jain, Dan G. Duda
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (6): 1557–1566.
https://doi.org/10.1158/1078-0432.CCR-12-3041
Published: 14 March 2013
View article titled, Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Open the PDF for Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study in another window
Includes: Supplementary data
Journal Articles

A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer Wheler, Donald Lawrence, Joseph Paul Eder, Colin J. Meyer, Deborah A. Ferguson, James Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Kufe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3396–3406.
https://doi.org/10.1158/1078-0432.CCR-11-2703
Published: 14 June 2012
View article titled, A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
Open the PDF for A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors

Andrew X. Zhu, Neal Ready, Jeffrey W. Clark, Howard Safran, Antonino Amato, Nadia Salem, Silvia Pace, Xiaoying He, Nela Zvereva, Thomas J. Lynch, David P. Ryan, Jeffrey G. Supko
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 374–381.
https://doi.org/10.1158/1078-0432.CCR-08-1024
Published: 31 December 2008
View article titled, Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia

Eyal C. Attar, Daniel J. DeAngelo, Jeffrey G. Supko, Ferdinando D'Amato, David Zahrieh, Andres Sirulnik, Martha Wadleigh, Karen K. Ballen, Steve McAfee, Kenneth B. Miller, James Levine, Ilene Galinsky, Elizabeth G. Trehu, David Schenkein, Donna Neuberg, Richard M. Stone, Philip C. Amrein
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1446–1454.
https://doi.org/10.1158/1078-0432.CCR-07-4626
Published: 03 March 2008
View article titled, Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
Open the PDF for Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia in another window
Journal Articles

Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors

Anna Berkenblit, Joseph P. Eder, Jr., David P. Ryan, Michael V. Seiden, Noriaki Tatsuta, Matthew L. Sherman, Thomas A. Dahl, Bruce J. Dezube, Jeffrey G. Supko
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 584–590.
https://doi.org/10.1158/1078-0432.CCR-06-0964
Published: 25 January 2007
View article titled, Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors
Open the PDF for Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors in another window
Journal Articles

The Effect of Enzyme-Inducing Antiseizure Drugs on the Pharmacokinetics and Tolerability of Procarbazine Hydrochloride

Stuart A. Grossman, Kathryn A. Carson, Tracy T. Batchelor, Glenn Lesser, Tom Mikkelsen, Jane B. Alavi, Surasak Phuphanich, Tarek Hammour, Joy D. Fisher, Jeffrey G. Supko
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5174–5181.
https://doi.org/10.1158/1078-0432.CCR-06-0932
Published: 01 September 2006
View article titled, The Effect of Enzyme-Inducing Antiseizure Drugs on the Pharmacokinetics and Tolerability of Procarbazine Hydrochloride
Open the PDF for The Effect of Enzyme-Inducing Antiseizure Drugs on the Pharmacokinetics and Tolerability of Procarbazine Hydrochloride in another window
Journal Articles

Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer

John R. Goffin, Ian C. Anderson, Jeffrey G. Supko, Joseph Paul Eder, Jr., Geoffrey I. Shapiro, Thomas J. Lynch, Margaret Shipp, Bruce E. Johnson, Arthur T. Skarin
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3417–3424.
https://doi.org/10.1158/1078-0432.CCR-04-2144
Published: 02 May 2005
View article titled, Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors

David P. Ryan, Joseph P. Eder, Jr., Thomas Puchlaski, Michael V. Seiden, Thomas J. Lynch, Charles S. Fuchs, Philip C. Amrein, Darrell Sonnichsen, Jeffrey G. Supko, Jeffrey W. Clark
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (7): 2222–2230.
https://doi.org/10.1158/1078-0432.CCR-0980-3
Published: 08 April 2004
View article titled, Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors
Open the PDF for Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors

Jeffrey G. Supko, Joseph P. Eder, Jr., David P. Ryan, Michael V. Seiden, Thomas J. Lynch, Phillip C. Amrein, Donald W. Kufe, Jeffrey W. Clark
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5178–5186.
Published: 12 November 2003
View article titled, Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors
Open the PDF for Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors in another window
Journal Articles

Phase I Clinical and Pharmacokinetic Study of Irinotecan in Adults with Recurrent Malignant Glioma

Mark R. Gilbert, Jeffrey G. Supko, Tracy Batchelor, Glenn Lesser, Joy D. Fisher, Steven Piantadosi, Stuart Grossman
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (8): 2940–2949.
Published: 11 August 2003
View article titled, Phase I Clinical and Pharmacokinetic Study of Irinotecan in Adults with Recurrent Malignant Glioma
Open the PDF for Phase I Clinical and Pharmacokinetic Study of Irinotecan in Adults with Recurrent Malignant Glioma in another window
Journal Articles

Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins

Rocio Garcia-Carbonero, Jeffrey G. Supko
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (3): 641–661.
Published: 01 March 2002
View article titled, Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins
Open the PDF for Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins in another window
Journal Articles

A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors

Michael V. Seiden, Shu-Wing Ng, Jeffrey G. Supko, David P. Ryan, Jeffrey W. Clark, Thomas Lynch, Kuan-Chun Huang, David Kwiatkowski, Arthur Skarin, Joseph P. Eder, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (3): 691–697.
Published: 01 March 2002
View article titled, A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors
Open the PDF for A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors in another window
Journal Articles

A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer

Panos Fidias, Jeffrey G. Supko, Renato Martins, Anthony Boral, Robert Carey, Michael Grossbard, Geoffrey Shapiro, Patricia Ostler, Joan Lucca, Bruce E. Johnson, Arthur Skarin, Thomas J. Lynch
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (12): 3942–3949.
Published: 01 December 2001
View article titled, A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Open the PDF for A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer in another window
Journal Articles

A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer

Geoffrey I. Shapiro, Jeffrey G. Supko, Angus Patterson, Cathy Lynch, Joan Lucca, Patrick F. Zacarola, Alona Muzikansky, John J. Wright, Thomas J. Lynch, Jr., Barrett J. Rollins
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (6): 1590–1599.
Published: 01 June 2001
View article titled, A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer
Open the PDF for A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer in another window